Eli Lilly Buys Kelonia Therapeutics for $3.2B
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly will acquire Kelonia Therapeutics for $3.2 billion, with milestone payments that could double the payout.
- Kelonia Therapeutics survived on $60 million in funding over five years and narrowly avoided running out of cash three times before the deal.
- Bryan Roberts of Venrock says Kelonia’s focused cell‑therapy platform and strategic positioning convinced Lilly to pay a premium.
- STAT+ podcast "The Readout Loud" highlights the acquisition as a rare “takeout” for a cash‑strapped biotech, underscoring the high‑stakes nature of the deal.
Why it matters: Eli Lilly secures a cell‑therapy platform, paying $3.2 billion for Kelonia while its investors cash out; the cash infusion accelerates Lilly’s oncology pipeline and speeds patient access to new cancer treatments.
